Identifying mutant-specific multi-drug combinations using comparative network reconstruction
Evert Bosdriesz (Vrije Universiteit Amsterdam)
João M. Fernandes Neto (Netherlands Cancer Institute)
Anja Sieber (Charité Universittsmedizin Berlin, Humboldt-Universitat zu Berlin)
R Bernards (Netherlands Cancer Institute)
Nils Blüthgen (Berlin Institute of Health (BIH), Charité Universittsmedizin Berlin, Humboldt-Universitat zu Berlin)
L.F.A. Wessels (TU Delft - Pattern Recognition and Bioinformatics, Netherlands Cancer Institute)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Targeted inhibition of aberrant signaling is an important treatment strategy in cancer, but responses are often short-lived. Multi-drug combinations have the potential to mitigate this, but to avoid toxicity such combinations must be selective and given at low dosages. Here, we present a pipeline to identify promising multi-drug combinations. We perturbed an isogenic PI3K mutant and wild-type cell line pair with a limited set of drugs and recorded their signaling state and cell viability. We then reconstructed their signaling networks and mapped the signaling response to changes in cell viability. The resulting models, which allowed us to predict the effect of unseen combinations, indicated that no combination selectively reduces the viability of the PI3K mutant cells. However, we were able to validate 25 of the 30 combinations that we predicted to be anti-selective. Our pipeline enables efficient prioritization of multi-drug combinations from the enormous search space of possible combinations.
help_outline